Key facts
as of Sep 2026- Kardigan’s last known valuation is $646.0M (Jan 2025).
- It has raised $554.0M across 1 recorded rounds; the latest was Early Stage VC (Series B) ($254.0M) in Oct 2025.
- Notable investors include Fidelity Management & Research Company, ARCH Venture Partners, T. Rowe Price Group, Perceptive Advisors, Sequoia Heritage — 7 tracked in total.
- 1 institutional filer reports fund marks on Kardigan across 3 filings.
- Status: Privately Held (backing).
PA Mark — composite indicative price
LOW confidence~$21per share
as of Sep 2026 · the exact daily mark is a member feature
Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Kardigan
Create free account
No card required
Recorded secondary trades
No prints on record
No secondary trades in Kardigan shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
1 filers · latest May 20261 SEC-registered fund reported 3 fair-value marks on Kardigan between Nov 2025 and May 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
1 roundsOct 2025Early Stage VC (Series B)$254.0M▮
About Kardigan
Operator of a heart health company intended to modernize cardiovascular drug development. The company specializes in matching critical disease drivers with treatment responders identified in clinical trials, enabling patients to have access to medicines that will cure their diseases.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2023
- Employees
- 135
- Website
- kardigan.bio/
- Ownership
- Privately Held (backing)